Format

Send to

Choose Destination
Oxid Med Cell Longev. 2017;2017:6781872. doi: 10.1155/2017/6781872. Epub 2017 May 4.

The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans.

Author information

1
Department of Hematology and Oncology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
2
Phuong Chau International Hospital, Can Tho, Vietnam.
3
Department of Physical Therapy, School of Health Sciences, Kanazawa University, Kanazawa, Japan.
4
Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.

Abstract

Preclinical studies have shown that resveratrol exerts immunomodulatory effects with potential clinical value in the amelioration of autoimmune disorders and cancer prevention; however, little is known about the in vivo effects of this naturally occurring polyphenol on human immune cells. We assessed the effects of repeated doses of resveratrol (1000 mg/day for 28 days) on circulating immune cells in healthy Japanese individuals. Resveratrol was safe and well tolerated and was associated with significant increases in the numbers of circulating γδ T cells and regulatory T cells and resulted in small, yet significant, decreases in the plasma levels of the proinflammatory cytokines TNF-α and MCP-1 and a significant increase in the plasma antioxidant activity compared with the corresponding antioxidant baseline activity and with that in four control individuals. In in vitro studies, resveratrol significantly improved the growth of γδ T cells and regulatory T cells. These findings demonstrate that resveratrol has some clear biological effects on human circulating immune cells. Further studies are necessary to interpret the long-term immunological changes associated with resveratrol treatment.

PMID:
28546852
PMCID:
PMC5435979
DOI:
10.1155/2017/6781872
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center